Amicus Therapeutics Inc
NASDAQ:FOLD
Amicus Therapeutics Inc
Revenue
Amicus Therapeutics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
Revenue
$399.4m
|
CAGR 3-Years
15%
|
CAGR 5-Years
34%
|
CAGR 10-Years
105%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Amicus Therapeutics Inc
Revenue Breakdown
Breakdown by Geography
Amicus Therapeutics Inc
Total Revenue:
399.4m
USD
|
Ex-United States:
252.4m
USD
|
United States:
146.9m
USD
|
Breakdown by Segments
Amicus Therapeutics Inc
See Also
What is Amicus Therapeutics Inc's Revenue?
Revenue
399.4m
USD
Based on the financial report for Dec 31, 2023, Amicus Therapeutics Inc's Revenue amounts to 399.4m USD.
What is Amicus Therapeutics Inc's Revenue growth rate?
Revenue CAGR 10Y
105%
Over the last year, the Revenue growth was 21%. The average annual Revenue growth rates for Amicus Therapeutics Inc have been 15% over the past three years , 34% over the past five years , and 105% over the past ten years .